Travere Therapeutics is Thursday's IBD Stock Of The Day. Shares are lingering around a buy zone after gapping up on an FDA ...

New understanding about the pathophysiology of the condition, along with new clinical trial endpoints for approval, have ...

Diabetic nephropathy is a common complication associated with diabetes that affects a person’s kidneys. Several medications may help slow the progression of kidney damage. Early treatment can prevent ...

Second agent targeting BAFF and APRIL appears effective in phase III trial ...

Dr Suneel Udani vividly recalls, as a first-year fellow, caring for a patient with IgA nephropathy whose condition deteriorated despite their best efforts, due to the limited treatment options ...

Climb Bio (NASDAQ:CLYM) outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C.

Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable ...

Medically reviewed by Matthew Wosnitzer, MD IgA nephropathy often begins silently, but early signs may include blood or foam ...

Diabetic nephropathy is the damage caused to the kidneys by diabetes mellitus. Around 50% of individuals with type 1 diabetes will develop nephropathy within 10 years of having the disease and around ...

IgA nephropathy (IgAN) is a kidney disorder caused by a buildup of immune complexes and the antibody called immunoglobulin A (IgA) inside the kidneys. This buildup causes inflammation in the kidneys.

A new pathologic classification scheme for diabetic nephropathy, in which only glomerular lesions are used to classify renal damage associated with either type 1 or type 2 diabetes, has been developed ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...